» Articles » PMID: 37074514

Preparation of MnO@poly-(DMAEMA-co-IA)-conjugated Methotrexate Nano-complex for MRI and Radiotherapy of Breast Cancer Application

Overview
Journal MAGMA
Publisher Springer
Date 2023 Apr 19
PMID 37074514
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: A novel efficient pH-sensitive targeted magnetic resonance imaging (MRI) contrast agent and innovative radio-sensitizing system were synthesized based on MnO NPs coated with biocompatible poly-dimethyl-amino-ethyl methacrylate-Co-itaconic acid, (DMAEMA-Co-IA) and targeted with methotrexate (MTX).

Materials And Methods: The as-established NPs were fully characterized and evaluated for MRI signal enhancement, relaxivity, in vitro cell targeting, cell toxicity, blood compatibility, and radiotherapy (RT) efficacy.

Results: The targeted NPs MnO@Poly(DMAEMA-Co-IA) and MTX-loaded NPs inhibited MCF-7 cell viability more effectively than free MTX after 24 and 48 h, respectively, with no noticeable toxicity. Additionally, the insignificant hemolytic activity demonstrated their proper hemo-compatibility. T-weighted magnetic resonance imaging was used to distinguish the differential uptake of the produced MnO@Poly(DMAEMA-Co-IA)-MTX NPs in malignant cells compared to normal ones in the presence of high and low MTX receptor cells (MCF-7 and MCF-10A, respectively). In MRI, the produced theranostic NPs displayed pH-responsive contrast enhancement. As shown by in vitro assays, treatment of cells with MnO@Poly(DMAEMA-Co-IA)-MTX NPs prior to radiotherapy in hypoxic conditions significantly enhanced therapeutic efficacy.

Conclusion: We draw the conclusion that using MnO@Poly(DMAEMA-Co-IA)-MTX NPs in MR imaging and combination radiotherapy may be a successful method for imaging and radiation therapy of hypoxia cells.

References
1.
Clarke J, Everest M . Cancer in the mass print media: fear, uncertainty and the medical model. Soc Sci Med. 2006; 62(10):2591-600. DOI: 10.1016/j.socscimed.2005.11.021. View

2.
Armitage E, Barbas C . Metabolomics in cancer biomarker discovery: current trends and future perspectives. J Pharm Biomed Anal. 2013; 87:1-11. DOI: 10.1016/j.jpba.2013.08.041. View

3.
Mortezazadeh T, Gholibegloo E, Alam N, Dehghani S, Haghgoo S, Ghanaati H . Gadolinium (III) oxide nanoparticles coated with folic acid-functionalized poly(β-cyclodextrin-co-pentetic acid) as a biocompatible targeted nano-contrast agent for cancer diagnostic: in vitro and in vivo studies. MAGMA. 2019; 32(4):487-500. DOI: 10.1007/s10334-019-00738-2. View

4.
James M, Gambhir S . A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012; 92(2):897-965. DOI: 10.1152/physrev.00049.2010. View

5.
Mansouri H, Gholibegloo E, Mortezazadeh T, Yazdi M, Ashouri F, Malekzadeh R . A biocompatible theranostic nanoplatform based on magnetic gadolinium-chelated polycyclodextrin: in vitro and in vivo studies. Carbohydr Polym. 2020; 254:117262. DOI: 10.1016/j.carbpol.2020.117262. View